CDC Recommends Routine Gardasil Vaccine for Boys!

by | Oct 26, 2011


A green chalkboard with the message 'I LOVE YOU' written in white chalk.In a shocking move, the Centers for Disease Control and Prevention said yesterday that the HPV vaccine Gardasil should be given to 11- to 12-year-old boys as well as girls.
The CDC’s Advisory Committee on Immunization Practices unanimously recommended routine vaccinations for boys to protect them from cancers related to the human papillomavirus, or HPV. Federal health officials usually adopt what the panel says and asks doctors and patients to follow the recommendations.
Merck & Co. designed Gardasil to prevent sexually transmitted HPV infections, which can lead to genital warts and cervical cancer in women, and cancer of the penis and anus in men. Merck won FDA approval for female patients in 2006, and male patients in 2009.
The problem, as we have pointed out previously, is that of the 100 different types of HPV, only fifteen might someday develop into cancer; moreover, the Journal of the American Medical Association says the relationship between infection with HPV at a young age and later development of cancer is unknown. Of those fifteen potential cancer-causing strains, the vaccine targets only two: HPV-16 and HPV-18. In other words, the vaccine will have no effect on 87% of the HPV viruses that might potentially cause cancer, and the causal link between HPV and cervical cancer is far from definitive.
According to Bloomberg.com, today’s finding reverses a 2009 recommendation by the panel that the HPV vaccine should be optional for boys. The panel at the time said the benefits of giving it routinely to 11- to 12- year-old boys wouldn’t justify the costs.
The CDC’s recommendation flies in the face of data from its own Vaccine Adverse Event Reporting System, which received a total of 18,727 reports of adverse events following Gardasil HPV vaccination. A whopping 1,498 of those events (8%) were considered “seriousâ€â€”such as blood clots, the neurological disorder Guillain-Barre Syndrome, and 68 reports of death. While the most common reactions might be redness or swelling at the injection site, to ignore or soft-pedal the existence of serious side effects (including death!) is not acceptable.
As our readers know, the HPV vaccine has been a national issue recently thanks to the GOP presidential debates. During this time, the major media have faithfully parroted the line that the vaccine is safe, and have refused to pay any attention whatever to the adverse event reports or the testimony of parents. The US government’s Institute of Medicine has also chosen to ignore the adverse event reports, saying disingenuously that they only consider peer-reviewed research. Unfortunately, both the major media and many of the IOM researchers depend on the drug companies for support, and it appears that we cannot expect anyone in an official position even to acknowledge, much less investigate, reports—often submitted by doctors—of what this vaccine is really doing.
It is outrageous that this vaccine has been mandated for girls in some states. To recommend it for boys is no less outrageous.
 

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

6 + 6 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });